Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$135.07
▼ $0.01 (-0.0%)
Market data updated: 09/20 02:00 AM
Fundamentals updated: 09/14/2026
News analyzed: 09/20/2026
Market Cap
Not available
Day Range
$135.06 - $135.09
52-Week Range
—
Beta
—
Next Earnings
09.11.2026
Support
$132.55
Resistance
$135.09
APGE is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+263.8% (1Y)
Strengths: 14/25 factors positiveRisk: Low
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Daily volatility (ATR)
ATR: 0.2% of price
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$71.50 vs. price $135.07 (-152.9%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 1 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 1
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
57
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
15d ago · $135.07
Evidence: Euphoria score crossed 55 (now 55)
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
55
Value
38
Momentum
70
Risk
70
Sentiment
100
Fundamental
50
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage for Apogee Therapeutics, Inc. has been limited to a single major event: its **acquisition by AbbVie for approximately $10.9 billion**, announced and completed on September 3, 2026. Under the deal, shareholders received $135.11 per share in cash. No other notable developments or recurring themes about Apogee were reported in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Apogee Therapeutics, Inc.. News trend score: 100. Reason: 11 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
55
🎯 Conviction (vs. Emotion)
52
Psychology
100
Fundamentals
50
Technical
70
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+55%
Market Narrative
65
Fundamental Reality
52
Narrative Gap
+13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant anchoring at resistance suggests traders are fixating on a specific price level, ignoring potential overvaluation signals (+27.3% above 200-day average) and extreme euphoria (RSI 77, 100/100 sentiment). FOMO and euphoria coexist, but the narrative gap (15-point divergence) hints at a disconnect between optimism and fundamentals. The key question: Will traders break free from resistance, or will anchoring persist despite overbought conditions? Overconfidence in momentum over fundamentals adds risk if fundamentals falter.
Updated: 09/09/2026, 03:12 AM
What could change this?
👥 What the crowd believes
"AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE)... total equity value of approximately $10.9 billion."
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 3/100
🗣️ Why do they disagree?
The stark divide in verdicts for APGE reflects deep methodological differences in how these investors assess risk, valuation, and market context. Benjamin Graham and his Enterprising Investor framework are stymied by insufficient data, while Walter Bagehot’s liquidity-focused approach sees it as resilient in a crisis—highlighting a contrast between valuation depth and defensive positioning. Meanwhile, the lowest scores from Fisher, Lynch, and Smith stem from missing fundamental or growth data, whereas Marks and Nelson flag late-cycle or overbought patterns, suggesting a cautionary view tied to macroeconomic timing. Loeb’s moderate score contrasts with the outright rejections from Veblen (growth-chasing) and the efficient-market camp (indexing as simpler), illustrating whether the stock’s profile aligns with contrarian, fundamental, or passive strategies.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 88
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 69
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 60
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 58
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 41
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 33
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 33
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 29
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 20
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 18
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 3
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Based on the last 270 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 4 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A pattern consistent with an early/mid distribution phase — a trading range after an advance with declining volume.
Medium confidence
$132.55
Range Bottom
$135.09
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-25.4%
ROA
-24.2%
ROIC
—
EPS
-$4.22
Cash
$131.55M
Total Debt
—
Current Ratio
18.55
Debt/Equity
0.00
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$135.07
Estimated Fair Value (DCF)
-$71.50
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-152.9%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-255.86M | $-234.73M |
| 2 | 8.1% | $-276.65M | $-232.85M |
| 3 | 6.3% | $-293.94M | $-226.97M |
| 4 | 4.4% | $-306.80M | $-217.34M |
| 5 | 2.5% | $-314.46M | $-204.38M |
Base FCF (last actual year)
$-232.60M
Terminal Value
$-4.96B
Present Value of Terminal Value
$-3.22B
Enterprise Value
$-4.34B
Net Debt
$0
Equity Value
$-4.34B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$12.35
Tangible Book Value per Share (Tangible NAV)
$2.98
Sentiment based on basic keywords (not AI) — 11 positive, 8 neutral, 1 negative out of the last 20 articles.
Insider Monkey · 9.9.2026
Yahoo · 3.9.2026
MT Newswires · 3.9.2026
MT Newswires · 3.9.2026
MT Newswires · 3.9.2026
Yahoo · 3.9.2026
MT Newswires · 3.9.2026
Yahoo · 3.9.2026
PR Newswire · 3.9.2026
Yahoo · 2.9.2026
MT Newswires · 2.9.2026
Yahoo · 30.8.2026
Simply Wall St. · 30.8.2026
Yahoo · 29.8.2026
Motley Fool · 29.8.2026
Trefis · 14.8.2026
Benzinga · 13.8.2026
24/7 Wall St. · 12.8.2026
Benzinga · 12.8.2026
MT Newswires · 12.8.2026
Apogee Therapeutics, Inc. (APGE) currently has a StockIQ AI score of 57/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
APGE currently scores 57/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, APGE's estimated fair value is -$71.50, which is 152.9% below the current price of $135.07. This is one valuation model among several signals in the fair-value category, not a price target.
APGE's technical score is 70/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 0.2% of price; Debt/equity: 0.00; Current ratio: 18.55.
Based on the real signals StockIQ computed: Estimated fair value: -$71.50 vs. price $135.07 (-152.9%); Return on equity (ROE): -25.4% (negative); Earnings per share (EPS) growth: -27.9%.
StockIQ has no recorded dividend payment history for APGE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Shah Nimish P | Disposition to the Company | 3.9.2026 | 6,743,321 | -6,743,321 | $135.11 |
| Shah Nimish P | Disposition to the Company | 3.9.2026 | 14,461 | -14,461 | — |
| HENDERSON MICHAEL THOMAS | Disposition to the Company | 3.9.2026 | 357,036 | -357,036 | — |
| HENDERSON MICHAEL THOMAS | Disposition to the Company | 3.9.2026 | 253,016 | -253,016 | — |
| Shah Nimish P | Disposition to the Company | 3.9.2026 | 7,657 | -7,657 | — |
| Shah Nimish P | Disposition to the Company | 3.9.2026 | 47,758 | -47,758 | — |
| Bollinger Lisa | Disposition to the Company | 3.9.2026 | 7,657 | -7,657 | — |
| Bollinger Lisa | Disposition to the Company | 3.9.2026 | 14,461 | -14,461 | — |
| Shah Nimish P | Disposition to the Company | 3.9.2026 | 365,853 | -365,853 | — |
| Shah Nimish P | Disposition to the Company | 3.9.2026 | 10,370 | -10,370 | — |
| Shah Nimish P | Disposition to the Company | 3.9.2026 | 1,750,000 | -1,750,000 | $135.11 |
| HENDERSON MICHAEL THOMAS | Disposition to the Company | 3.9.2026 | 920,941 | -920,941 | — |
| HENDERSON MICHAEL THOMAS | Disposition to the Company | 3.9.2026 | 387,012 | -387,012 | — |
| Bollinger Lisa | Disposition to the Company | 3.9.2026 | 18,550 | -18,550 | — |
| Bollinger Lisa | Disposition to the Company | 3.9.2026 | 8,112 | -8,112 | — |
| Fox Jennifer A. | Disposition to the Company | 3.9.2026 | 7,657 | -7,657 | — |
| Dambkowski Carl | Disposition to the Company | 3.9.2026 | 83,690 | -83,690 | — |
| Fairmount Funds Management LLC | Disposition to the Company | 3.9.2026 | 14,461 | -14,461 | — |
| Fox Jennifer A. | Disposition to the Company | 3.9.2026 | 14,461 | -14,461 | — |
| Dambkowski Carl | Disposition to the Company | 3.9.2026 | 167,123 | -167,123 | — |
| JONES WILLIAM A JR | Disposition to the Company | 3.9.2026 | 7,657 | -7,657 | — |
| Fox Jennifer A. | Disposition to the Company | 3.9.2026 | 34,824 | -34,824 | — |
| Henderson Jane | Disposition to the Company | 3.9.2026 | 83,690 | -83,690 | — |
| Henderson Jane | Disposition to the Company | 3.9.2026 | 124,962 | -124,962 | — |
| Henderson Jane | Disposition to the Company | 3.9.2026 | 175,345 | -175,345 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,203,052 shares short as of 2026-08-31 · vs. 4,217,209 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
29.5% of trading volume this week was short selling, vs. 29.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology